Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROH-201 ophthalmic solution Phase II trial in vernal keratoconjunctivitis
jRCT2031250618Phase 2Not yet recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of delgocitinib in Vernal Keratoconjunctivitis (VKC), sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Change in clinical signs. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
delgocitinib
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on jRCT2031250618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250618.